Clomethiazole API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Clomethiazole API 533-45-9?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Clomethiazole. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Clomethiazole
- Synonyms:
- Clomethiazolum , Clometiazol
- Cas Number:
- 533-45-9
- DrugBank number:
- DB06470
- Unique Ingredient Identifier:
- 0C5DBZ19HV
General Description:
Clomethiazole, identified by CAS number 533-45-9, is a notable compound with significant therapeutic applications. Clomethiazole is a well-established γ-aminobutyric acid (GABAA)-mimetic drug. It is a sedative and hypnotic that is widely used in treating and preventing symptoms of acute alcohol withdrawal. It is a drug which is structurally related to thiamine (vitamin B1) but acts like a sedative, hypnotic, muscle relaxant and anticonvulsant. It is also used for the management of agitation, restlessness, short-term insomnia and Parkinson's disease in the elderly.
Indications:
This drug is primarily indicated for: Investigated for use/treatment in strokes. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Clomethiazole functions by: clomethiazole interacts with the GABAA receptor complex. It inhibits the binding of butyl-bicyclophosphorothionate (TBPS), an effect indicative of GABAA receptor-channel activation, by increasing the rate of TBPS dissociation and decreasing the binding affinity. Gamma-aminobutyric acid (GABA), acting at GABAA receptors, is the main fast inhibitory neurotransmitter in mammalian central nervous system. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Clomethiazole belongs to the class of organic compounds known as 4,5-disubstituted thiazoles. These are compounds containing a thiazole ring substituted at positions 4 and 5 only, classified under the direct parent group 4,5-disubstituted thiazoles. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Azoles class, specifically within the Thiazoles subclass.
Categories:
Clomethiazole is categorized under the following therapeutic classes: Anticonvulsants, Central Nervous System Agents, Central Nervous System Depressants, Compounds used in a research, industrial, or household setting, Cytochrome P-450 CYP2A6 Substrates, Cytochrome P-450 CYP2B6 Substrates, Cytochrome P-450 CYP2C19 Substrates, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 Substrates, GABA Agents, GABA Modulators, Hypnotics and Sedatives, Nervous System, Neuroprotective Agents, Neurotransmitter Agents, Protective Agents, Psycholeptics, Sulfur Compounds, Thiazoles. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Clomethiazole is a type of Anticonvulsants
Anticonvulsants are a vital category of pharmaceutical Active Pharmaceutical Ingredients (APIs) used for the treatment of seizures and epilepsy. These APIs play a crucial role in managing and preventing convulsions, which are characterized by abnormal electrical activity in the brain. With a significant demand for effective anticonvulsant medications, these APIs hold immense importance in the pharmaceutical industry.
Anticonvulsant APIs work by stabilizing the excessive electrical activity in the brain, preventing or reducing seizures. They achieve this by targeting specific receptors or channels involved in the regulation of neuronal excitability. Some commonly used anticonvulsant APIs include phenytoin, valproic acid, carbamazepine, and lamotrigine.
Pharmaceutical companies utilize these APIs to formulate various dosage forms, such as tablets, capsules, and oral suspensions, ensuring convenient administration for patients. Additionally, anticonvulsant APIs may also be employed in the development of extended-release formulations, providing sustained and controlled drug release.
The market for anticonvulsant APIs continues to grow due to the rising prevalence of epilepsy and other seizure disorders. Moreover, ongoing research and development efforts aim to enhance the efficacy, safety, and tolerability of these APIs, ensuring better treatment outcomes for patients.
In conclusion, anticonvulsant APIs are a crucial pharmaceutical category used to manage seizures and epilepsy. With their ability to stabilize brain activity, these APIs play a pivotal role in improving the quality of life for individuals living with these conditions. The pharmaceutical industry's continued focus on research and development in this area ensures the availability of advanced and effective anticonvulsant medications for patients in need.
